AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts

WILMINGTON, Del., November 02, 2007 /PRNewswire-FirstCall/ -- AstraZeneca is disappointed with today's ruling and we intend to appeal. We believe the ruling is unsupported as the conduct at issue was the result of highly competitive conditions in the pharmaceutical marketplace, which led to discounting. The Court's prior ruling on liability is thus profoundly anti- competitive.

AstraZeneca has competed responsibly with respect to pricing and marketing of drugs and we firmly believe that we have acted at all times in accordance with the law.

The plaintiffs are fully aware of AWP pricing and still use AWP as a reimbursement benchmark today. The result of AstraZeneca's conduct in this case was to keep a lower cost product competitive under the Government's reimbursement system, thereby saving Medicare and patients millions of dollars.

CONTACT: Tony Jewell, +1-302-885-4594, , orLaura Woodin, +1-302-885-1087, , both ofAstraZeneca Tony.Jewell@AstraZeneca.com Laura.Woodin@AstraZeneca.com

Web site: http://www.astrazeneca-us.com//

Company News On-Call: http://www.prnewswire.com/comp/985887.html /

Ticker Symbol: (NYSE:AZN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: November 2007


View comments

Hide
(web4)